Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Rectal Neoplasms 20Colonic Neoplasms 20Carcinoma, Renal Cell 17Fallopian Tube Neoplasms 15Breast Neoplasms 13Ovarian Neoplasms 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Brain Neoplasms 10Neoplasms 9Glioblastoma 9Brenner Tumor 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Pancreatic Neoplasms 7Melanoma 7Oligodendroglioma 6Gliosarcoma 6Glioma 6Breast Neoplasms, Male 6Adenocarcinoma of Lung 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Astrocytoma 5Adenocarcinoma, Bronchiolo-Alveolar 5Uterine Cervical Neoplasms 4Salivary Gland Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Carcinoma, Hepatocellular 4Unspecified Adult Solid Tumor, Protocol Specific 3

Interventions

montanide ISA 51 1flt3 ligand protein 1Thalidomide 1MART-1 Antigen 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Urologic Neoplasms × Bevacizumab × Clear all
NCT00019539 2024-03-04

Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Genitourinary

Carcinoma, Renal Cell, Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡